Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

NCT07190053 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Enthesitis-related Arthritis (ERA)
Juvenile Psoriatic Arthritis (JPsA)

Interventions

OTHER: Secukinumab

Sponsor

Novartis Pharmaceuticals